Growth Metrics

Carlsmed (CARL) EBIT Margin (2024 - 2026)

Carlsmed posted quarterly EBIT Margin of 57.56% for Q1 2026, down 143.0% year-on-year from 133.86% in Q1 2025, and up 6.33% on a QoQ basis from 61.44% in Q4 2025.

Carlsmed (CARL) has 3 years of EBIT Margin data on file, last reported at 57.56% in Q1 2026.

  • For the quarter ending Q1 2026, EBIT Margin fell 143.0% year-over-year to 57.56%; the trailing twelve-month figure through Mar 2026 stood at 60.48% (up 1549.0% YoY), and the FY2025 full-year result was 60.53%, up 2827.0% from the prior year.
  • EBIT Margin for Q1 2026 stood at 57.56%, up from 61.44% in the prior quarter.
  • Across five years, EBIT Margin topped out at 49.93% in Q4 2024 and bottomed at 118.01% in Q3 2024.
  • The 3-year median for EBIT Margin is 59.5% (2025), against an average of 71.24%.
  • Peak annual rise in EBIT Margin reached 5010 bps in 2025, while the deepest fall reached 1152 bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 49.93% in 2024, then declined by 23 bps to 61.44% in 2025, then increased by 6 bps to 57.56% in 2026.
  • The last three EBIT Margin figures came in at 57.56% (Q1 2026), 61.44% (Q4 2025), and 69.11% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn 29.41%
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 3.36%
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 29.03%
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn 17.59%
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn 17.08%
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 25.64%
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -11.30%
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn 1.23%
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn 5.44%
10 Carlsmed 298.68 Mn 201.48 Mn 12.43 Mn -57.56%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -57.56%
Dec 31, 2025 -61.44%
Sep 30, 2025 -69.11%
Jun 30, 2025 -53.81%
Mar 31, 2025 -56.13%
Dec 31, 2024 -49.93%
Sep 30, 2024 -118.01%
Jun 30, 2024 -103.91%